Sign Out
Losartan is contraindicated in pregnancy since it has been associated with fetal toxicity in animal studies and other drugs that act on the renin-angiotensin system, such as ACE inhibitors, have been associated with fetal toxicity in humans.
Losartan must be discontinued as soon as pregnancy is detected. Drugs that are directly on the renin-angiotensin system can cause injury and even death in the developing fetus, particularly during the second and third trimesters. Fetal renal perfusion, which is dependent upon the development of the renin angiotensin system, begins in the second trimester.
Losartan should be used with caution during breast-feeding as it is not known whether it is excreted in human milk. Safety and effectiveness in children have not been established.
